Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute AstraZeneca Massachusetts General Hospital |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00372515 |
The primary purposes of this study are to find out if using high doses of the drug Gefitinib (Iressa) as a way to treat patients with non-small cell lung cancer that has spread to the covering of the brain and/or spinal cord (meninges) results in any bad side effects; and to determine the highest dose that can be given to patients in this setting.
Condition | Intervention | Phase |
---|---|---|
Non-Small Cell Lung Cancer |
Drug: Gefitinib |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations |
Estimated Enrollment: | 18 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Bruce Johnson, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( David Jackman, MDq ) |
Study ID Numbers: | 05-403 |
Study First Received: | September 6, 2006 |
Last Updated: | April 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00372515 History of Changes |
Health Authority: | United States: Food and Drug Administration |
epidermal growth factor EGFR lung cancer Iressa Gefitinib |
Thoracic Neoplasms Meningeal Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Protein Kinase Inhibitors Meningitis Carcinoma Respiratory Tract Diseases Central Nervous System Infections |
Lung Neoplasms Lung Diseases Mitogens Non-small Cell Lung Cancer Gefitinib Carcinoma, Non-Small-Cell Lung Nervous System Neoplasms Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Meningeal Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Central Nervous System Neoplasms Protein Kinase Inhibitors Meningitis Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Gefitinib Nervous System Neoplasms |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Nervous System Diseases Central Nervous System Diseases Enzyme Inhibitors Pharmacologic Actions Carcinoma Neoplasms Central Nervous System Infections Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |